Tag: tyrosine kinase inhibitor

Eisai

Eisai Enters Into License Agreement with SciClone for Development and Commercialization of Tasulgratinib in China, Hong Kong, Macau and Taiwan

Eisai Co., Ltd. announced that it has signed a license agreement with SciClone Pharmaceuticals Limited to grant exclusive…

By

NewsDesk

Join Our Community

First Name

Last Name

Email Address

Country

I have read and agree to the Terms & Conditions

Join Our Community

First Name

Last Name

Email Address

Country

I have read and agree to the Terms & Conditions